talabostat mesylate

TERMINATED · PHASE3 · Carcinoma, Non-Small Cell Lung

FDA Hold May 2007

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.